TBWCX
Price
$22.13
Change
+$0.24 (+1.10%)
Updated
Jun 2 closing price
Net Assets
470.99M
VGTSX
Price
$27.93
Change
+$0.17 (+0.61%)
Updated
Jun 2 closing price
Net Assets
629.15B
Interact to see
Advertisement

TBWCX vs VGTSX

Header iconTBWCX vs VGTSX Comparison
Open Charts TBWCX vs VGTSXBanner chart's image
TBWCX vs VGTSX Comparison Chart in %
View a ticker or compare two or three
VS
TBWCX vs. VGTSX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TBWCX is a Hold and VGTSX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VGTSX has more cash in the bank: 629B vs. TBWCX (471M). VGTSX pays higher dividends than TBWCX: VGTSX (2.56) vs TBWCX (0.33). TBWCX was incepted earlier than VGTSX: TBWCX (11 years) vs VGTSX (30 years). TBWCX (2.62) is less costly to investors than VGTSX (0.17). TBWCX is a more actively managed with annual turnover of: 39.30 vs. VGTSX (4.00). VGTSX has a lower initial minimum investment than TBWCX: VGTSX (0) vs TBWCX (5000). VGTSX annual gain was more profitable for investors over the last year : 28.97 vs. TBWCX (11.04). VGTSX return over 5 years is better than : 35.12 vs. TBWCX (9.34).
TBWCXVGTSXTBWCX / VGTSX
Total Expense Ratio1.950.171,147%
Annual Report Gross Expense Ratio2.620.171,541%
Fund Existence11 years30 years-
Gain YTD3.01214.60321%
Front LoadN/AN/A-
Min. Initial Investment50000-
Min. Initial Investment IRAN/AN/A-
Net Assets471M629B0%
Annual Yield % from dividends0.332.5613%
Returns for 1 year11.0428.9738%
Returns for 3 years34.8859.3459%
Returns for 5 years9.3435.1227%
Returns for 10 years77.89103.9775%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LIQT1.160.11
+10.07%
LiqTech International
MTUS20.360.80
+4.09%
Metallus
VEON55.300.21
+0.38%
VEON Ltd
RYAAY58.72-0.64
-1.08%
Ryanair Holdings plc
GALT2.42-0.19
-7.28%
Galectin Therapeutics